None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME (2013) J Clin Psychopharmacol 33(5): 658-66
    › Primary publication · 23857311 (PubMed)
  2. Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. Simmler LD, Wandeler R, Liechti ME (2013) BMC Res Notes : 220
    › Primary publication · 23734766 (PubMed) · PMC3679734 (PubMed Central)
  3. Pharmacological characterization of designer cathinones in vitro. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Br J Pharmacol 168(2): 458-70
    › Primary publication · 22897747 (PubMed) · PMC3572571 (PubMed Central)
  4. Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Huwyler J, Hoener MC, Liechti ME (2012) PLoS One 7(5): e36476
    › Primary publication · 22574166 (PubMed) · PMC3344887 (PubMed Central)
  5. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Hysek C, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, Liechti ME (2012) Br J Pharmacol 166(8): 2277-88
    › Primary publication · 22404145 (PubMed) · PMC3448893 (PubMed Central)
  6. Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, Liechti ME (2012) J Pharmacol Exp Ther 340(2): 286-94
    › Primary publication · 22034656 (PubMed)
  7. Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. Simmler LD, Hysek CM, Liechti ME (2011) J Clin Endocrinol Metab 96(9): 2844-50
    › Primary publication · 21715530 (PubMed)
  8. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) Clin Pharmacol Ther 90(2): 246-55
    › Primary publication · 21677639 (PubMed)
  9. Investigation of different formulations for drug delivery through the nail plate. Vejnovic I, Simmler L, Betz G (2010) Int J Pharm 386(1-2): 185-94
    › Primary publication · 19941943 (PubMed)